OmniComm’s TrialMaster EDC suite will be used for the collection of clinical data during a five year term in global Phase I to Phase III clinical studies.
OmniComm Systems, a leading provider of clinical data management technology, announced the signing of a five-year agreement with a Canadian pharmaceutical drug developer. OmniComm’s TrialMaster electronic data capture (EDC) suite will be used for the collection of clinical data during this five year term in numerous global trials spanning Phase I to Phase III clinical studies.
Read the full release.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.